Journal
CANCER CELL
Volume 7, Issue 5, Pages 457-468Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2005.03.035
Keywords
-
Categories
Funding
- NCI NIH HHS [CA90917, CA78810] Funding Source: Medline
- NHLBI NIH HHS [HL54131] Funding Source: Medline
Ask authors/readers for more resources
Anticancer agents that selectively kill tumor cells and spare normal tissues are urgently needed. Here, we engineered a cell-permeable peptidomimetic, shepherdin, modeled on the binding interface between the molecular chaperone Hsp90 and the antiapoptotic and mitotic regulator, survivin. Shepherdin makes extensive contacts with the ATIP pocket of Hsp90, destabilizes its client proteins, and induces massive death of tumor cells by apoptotic and nonapoptotic mechanisms. Conversely, shepherdin does not reduce the viability of normal cells, and does not affect colony formation of purified hematopoietic progenitors. Systemic administration of shepherdin in vivo is well tolerated, and inhibits human tumor growth in mice without toxicity. Shepherdin could provide a potent and selective anticancer agent in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available